Molecular Medicine

Table 3 Therapeutic effectiveness of anti-MDM2 oligonucleotide administered alone or in combination with cytotoxic agents in mice bearing human colon cancer DLD-1 xenografts

From: Anti-Tumor Efficacy of a Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in Human Colon Cancer Models: p53-Dependent and p53-Independent Mechanisms

			+ ASM		+ Anti-MDM2 AS
Day		No Oligo [1] (% T:C)	[2] (% T:C)	Ratio (%) ([2]/[1])	[3] (% T:C)	Ratio (%) ([3]/[1])
3	Oligo alone	100	82	82	77	77
	HCPT	88	93	106	80	91
	5-FU	79	85	108	74	93
6	Oligo alone	100	88	88	72	72
	HCPT	74	69	93	56	76
	5-FU	76	86	113	65	85
9	Oligo alone	100	79	70	59	59
	HCPT	62	62	99	41	65
	5-FU	61	65	106	58	95
12	Oligo alone	100	66	66	41	41
	HCPT	51	49	96	28	54
	5-FU	46	54	118	38	83
15	Oligo alone	100	79	79	44	44
	HCPT	61	58	95	28	45
	5-FU	54	51	93	42	78
18	Oligo alone	100	81	81	47	47
	HCPT	56	52	92	27	49
	5-FU	56	46	83	33	60
21	Oligo alone	100	76	76	37	37
	HCPT	51	45	88	20	39
	5-FU	44	43	97	23	53

Back to article page

ISSN: 1528-3658

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com